Current Complaints | Help Center| Subscribe

Recent:

Data for the month ending - Aug, 2026

Sr. No.	Received from	Pending at the end of last month	Received	Resolved*	Total Pending #	Pending complaints >3months	Average Resolution time^ (in days)
1	Directly from Investors	0	0	0	0	0	0
2	SEBI (SCORES)	0	0	0	0	0	0
3	Other Sources (if any)	0	0	0	0	0	0
	Grand Total	0	0	0	0	0	0

^ Average Resolution time is the sum total of time taken to resolve each complaint in days, in the current month divided by total number of complaints resolved in the current month.

Trend of Monthly Disposal of Complaints

Sr. No.	Month	Carried forward from previous month	Received	Resolved*	Pending#
1	Jun, 2026	0	0	0	0
2	Jul, 2026	0	0	0	0
3	Aug, 2026	0	0	0	0
	Grand Total	0	0	0	0

*Inclusive of complaints of previous months resolved in the current month. #Inclusive of complaints pending as on the last day of the month.

Trend of Annual Disposal of Complaints

Sr. No.	Fin. Year	Received	Resolved*
1	2022-23	1	1
2	2023-24	0	0
3	2024-25	0	0
4	2025-26	1	1
	Grand Total	2	2

*Inclusive of complaints of previous months resolved in the current month. #Inclusive of complaints pending as on the last day of the year.

Zydus Lifesciences gets in principle acceptability from WHO for ZyVac TCV

Zydus Lifesciences Ltd. | Pharmaceuticals & Drugs | Healthcare | BSE: 532321 | NSE: ZYDUSLIFE

23 Oct 2024 Evaluate

Zydus Lifesciences has received in principle acceptability from World Health Organisation (WHO) for ZyVac TCV. ZyVac TCV is now eligible for purchase by United Nations (UN) agencies. ZyVac TCV is indigenously developed and manufactured at the Zydus Biotech Park, Ahmedabad.

ZyVac TCV is indicated for active immunization against Salmonella typhi infection in the age group of 6 months to 65 years. This prequalification for ZyVac TCV makes it eligible to be part of UN agencies procurement programme. Annually over 150 million doses of the typhoid conjugate vaccine is procured by UN agencies to prevent this infectious disease in geographies where it is most prevalent, such as India, Africa and Southeast Asia.

Zydus Lifesciences (formerly known as Cadila Healthcare) is an India-based pharmaceutical company.

Peers

Company Name	CMP
Sun Pharma. Inds.	1752.10
Dr. Reddys Labs.	1232.90
Cipla	1330.60
Lupin	1966.30
Zydus Lifesciences	1123.10
View more..

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045

Compliance Officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com	Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com	Telephone: +919860919463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com	Telephone: +919175899463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.